Journal article
A network pharmacology study of the multi-targeting profile of an antiarrhythmic Chinese medicine Xin Su Ning
- Abstract:
- Xin Su Ning (XSN) is a China patented and certified traditional Chinese herbal medicine used to treat premature ventricular contractions (PVCs) since 2005. XSN is formulated with 11 herbs, designed to treat arrhythmia with phlegm-heat heart-disturbed syndrome (PHHD) according to Chinese medicine theory. The rational compatibility of the 11 herbs decides the therapeutic outcome of XSN. Due to the multicomponent nature of traditional Chinese medicine, it is difficult to use conventional pharmacology to interpret the therapeutic mechanism of XSN in terms of clear-cut drug molecule and target interactions. Network pharmacology/systematic pharmacology usually consider all the components in a formula with the same weight; therefore, the proportion of the weight of the components has been ignored. In the present study, we introduced a novel coefficient to mimic the relative amount of all the components in relation with the weight of the corresponding herb in the formula. The coefficient is also used to weigh the pharmacological effect of XSN on all relative biological pathways. We also used the cellular electrophysiological data generated in our lab, such as the effect of liensinine and isoliquiritigenin on NaV1.5 channels; we therefore set sodium channel as one of the targets of these two components, which would support the clinical efficacy of XSN in treating tachyarrhythmia. Combining the collected data and our discovery, a panoramagram of the pharmacological mechanism of XSN was established. Pathway enrichment and analysis showed that XSN treated PHHD arrhythmia through multiple ion channels regulation, protecting the heart from I/R injury, inhibiting the apoptosis of cardiomyocyte, and improving glucose and lipid metabolism.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 5.6MB, Terms of use)
-
- Publisher copy:
- 10.3389/fphar.2019.01138
Authors
- Publisher:
- Frontiers Media
- Journal:
- Frontiers in Pharmacology More from this journal
- Volume:
- 10
- Article number:
- 1138
- Publication date:
- 2019-09-25
- Acceptance date:
- 2019-09-04
- DOI:
- EISSN:
-
1663-9812
- Pmid:
-
31607935
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:1061705
- UUID:
-
uuid:b101e857-e903-4bdd-99d1-d31bed8ae3a2
- Local pid:
-
pubs:1061705
- Source identifiers:
-
1061705
- Deposit date:
-
2019-10-22
Terms of use
- Copyright holder:
- Wang et al
- Copyright date:
- 2019
- Notes:
- Copyright © 2019 Wang, Streeter, Wang, Purnama, Lyu, Carr and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record